These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21773691)

  • 1. Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients.
    Shiohira S; Yoshida T; Sugiura H; Yoshida S; Mitobe M; Shimada K; Ohba T; Tsuchiya K; Kabaya T; Nitta K
    Clin Exp Nephrol; 2011 Dec; 15(6):893-9. PubMed ID: 21773691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease.
    Ishii H; Kumada Y; Toriyama T; Aoyama T; Takahashi H; Yamada S; Yasuda Y; Yuzawa Y; Maruyama S; Matsuo S; Matsubara T; Murohara T
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1034-40. PubMed ID: 18322041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Young IS; Lee B; Soong CV
    J Vasc Surg; 2009 May; 49(5):1226-34. PubMed ID: 19217745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of rotigotine on clinical symptoms, quality of life and sleep hygiene adequacy in haemodialysis-associated restless legs syndrome.
    Esteve V; Carneiro J; Salazar G; Pou M; Tapia I; Fulquet M; Duarte V; Saurina A; Moreno F; Ramírez de Arellano M
    Nefrologia (Engl Ed); 2018; 38(1):79-86. PubMed ID: 29198453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cilostazol for peripheral arterial disease.
    Robless P; Mikhailidis DP; Stansby GP
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003748. PubMed ID: 18254032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cilostazol for peripheral arterial disease.
    Robless P; Mikhailidis DP; Stansby GP
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003748. PubMed ID: 17253494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Makar RR; Young IS; Lee B; Soong CV
    Vasc Endovascular Surg; 2009; 43(2):132-43. PubMed ID: 19131370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for restless legs syndrome in hemodialysis patients in Taiwan: A case-control study.
    Tsai LH; See LC; Chien CC; Chen CM; Chang SH
    Medicine (Baltimore); 2019 Dec; 98(51):e18450. PubMed ID: 31861018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilostazol May Decrease Plasma Inflammatory Biomarkers in Patients with Recent Small Subcortical Infarcts: A Pilot Study.
    Saji N; Tone S; Murotani K; Yagita Y; Kimura K; Sakurai T
    J Stroke Cerebrovasc Dis; 2018 Jun; 27(6):1639-1645. PubMed ID: 29454567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Cilostazol Therapy in Hemodialysis Patients with Asymptomatic Peripheral Arterial Disease: A Retrospective Cohort Study.
    Lim PS; Jeng Y; Wu MY; Pai MA; Wu TK; Chen CH
    Biomed Res Int; 2016; 2016():8236903. PubMed ID: 27747241
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease.
    Ishii H; Aoyama T; Takahashi H; Kumada Y; Kamoi D; Sakakibara T; Umemoto N; Suzuki S; Tanaka A; Ito Y; Murohara T
    J Cardiol; 2016 Feb; 67(2):199-204. PubMed ID: 26074442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study design and rationale of "Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial.
    Ko YG; Kim BK; Lee BK; Kang WC; Choi SH; Kim SW; Lee JH; Lee M; Honda Y; Fitzerald PJ; Shim WH;
    Trials; 2011 Jan; 12():10. PubMed ID: 21226953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
    Shigematsu H; Nishibe T; Obitsu Y; Matsuzaki K; Ishida A; Miyata T; Shindo S; Hida K; Ohta T; Ando M; Kawasaki T; Yasugi T; Matsumoto T
    Int Angiol; 2010 Apr; 29(2 Suppl):2-13. PubMed ID: 20357743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up.
    Ahn CM; Hong SJ; Park JH; Kim JS; Lim DS
    Heart Vessels; 2011 Sep; 26(5):502-10. PubMed ID: 21153029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients.
    Ohtake T; Sato M; Nakazawa R; Kondoh M; Miyaji T; Moriya H; Hidaka S; Kobayashi S
    Ther Apher Dial; 2014 Feb; 18(1):1-8. PubMed ID: 24499078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gabapentin versus levodopa-c for the treatment of restless legs syndrome in hemodialysis patients: a randomized clinical trial.
    Razazian N; Azimi H; Heidarnejadian J; Afshari D; Ghadami MR
    Saudi J Kidney Dis Transpl; 2015 Mar; 26(2):271-8. PubMed ID: 25758874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.
    Elam MB; Heckman J; Crouse JR; Hunninghake DB; Herd JA; Davidson M; Gordon IL; Bortey EB; Forbes WP
    Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1942-7. PubMed ID: 9848888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of restless legs syndrome with oxidative stress and inflammation in patients undergoing hemodialysis.
    Higuchi T; Abe M; Mizuno M; Yamazaki T; Suzuki H; Moriuchi M; Oikawa O; Okawa E; Ando H; Okada K
    Sleep Med; 2015 Aug; 16(8):941-8. PubMed ID: 26070856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol.
    Soga Y; Iida O; Hirano K; Suzuki K; Yokoi H; Nobuyoshi M
    Catheter Cardiovasc Interv; 2012 Mar; 79(4):541-8. PubMed ID: 21805619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.
    Grouse JR; Allan MC; Elam MB
    J Clin Pharmacol; 2002 Dec; 42(12):1291-8. PubMed ID: 12463722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.